journal
https://read.qxmd.com/read/37802675/advancements-in-positron-emission-tomography-detectors-from-silicon-photomultiplier-technology-to-artificial-intelligence-applications
#21
REVIEW
Jae Sung Lee, Min Sun Lee
This review article focuses on PET detector technology, which is the most crucial factor in determining PET image quality. The article highlights the desired properties of PET detectors, including high detection efficiency, spatial resolution, energy resolution, and timing resolution. Recent advancements in PET detectors to improve these properties are also discussed, including the use of silicon photomultiplier technology, advancements in depth-of-interaction and time-of-flight PET detectors, and the use of artificial intelligence for detector development...
October 4, 2023: PET Clinics
https://read.qxmd.com/read/37336693/ai-enhanced-pet-and-mr-imaging-for-patients-with-breast-cancer
#22
REVIEW
Valeria Romeo, Linda Moy, Katja Pinker
New challenges are currently faced by clinical and surgical oncologists in the management of patients with breast cancer, mainly related to the need for molecular and prognostic data. Recent technological advances in diagnostic imaging and informatics have led to the introduction of functional imaging modalities, such as hybrid PET/MR imaging, and artificial intelligence (AI) software, aimed at the extraction of quantitative radiomics data, which may reflect tumor biology and behavior. In this article, the most recent applications of radiomics and AI to PET/MR imaging are described to address the new needs of clinical and surgical oncology...
October 2023: PET Clinics
https://read.qxmd.com/read/37296043/breast-cancer-screening-and-diagnosis-recent-advances-in-imaging-and-current-limitations
#23
REVIEW
Alison R Gegios, Molly S Peterson, Amy M Fowler
Breast cancer detection has a significant impact on population health. Although there are many breast imaging modalities, mammography is the predominant tool for breast cancer screening. The introduction of digital breast tomosynthesis to mammography has contributed to increased cancer detection rates and decreased recall rates. In average-risk women, starting annual screening mammography at age 40 years has demonstrated the highest mortality reduction. In intermediate- and high-risk women as well as in those with dense breasts, additional modalities, including MRI, ultrasound, and molecular breast imaging, can also be considered for adjunct screening to improve the detection of mammographically occult malignancy...
October 2023: PET Clinics
https://read.qxmd.com/read/37778967/developments-in-dedicated-prostate-pet-instrumentation
#24
REVIEW
Antonio J Gonzalez, Andrea Gonzalez-Montoro
This article summarizes the evolution of dedicated prostate PET instrumentation. It starts by introducing prostate cancer, as well as the most common diagnostic and staging methods that are used in the clinics. Then, it describes the key aspects of PET detectors and their assembly in full PET scanners highlighting the most suitable geometries for prostate examination, and a review on the existing prostate dedicated PET. Finally, the next steps for extending the use of PET in the daily diagnose, staging, and image-guided biopsy of patients with prostate cancer are discussed...
September 29, 2023: PET Clinics
https://read.qxmd.com/read/37777381/potential-clinical-applications-of-dedicated-prostate-positron-emission-tomography
#25
REVIEW
Paolo Castellucci, Riccardo Mei, Andrea Farolfi, Cristina Nanni, Stefano Fanti
The diagnosis of prostate cancer (PCa) is usually based on transrectal or transperineal biopsies (from 12 to 24 samples) in most cases after the performance of a dedicated MRI and/or transrectal ultrasound. A small-dedicated PET scanner could improve spatial resolution and increase sensitivity, allowing a precise detection and location of the PCa foci, thus allowing an image-guided biopsy. In this short review, we will focus our attention on the potential application of a dedicated prostate PET scanner and on the prototype that has been already assembled for this purpose...
September 28, 2023: PET Clinics
https://read.qxmd.com/read/37775372/high-resolution-imaging-using-virtual-pinhole-pet-concept
#26
REVIEW
Yuan-Chuan Tai
Organ-specific PET scanners continues to draw interest for their high-resolution imaging capability that is unmatched by whole-body PET/computed tomography (CT) scanners. The virtual-pinhole PET concept offers new opportunities in PET system design, allowing one to mix and match detectors of different characteristics to achieve the highest performance such as high image resolution, high system sensitivity, and large imaging field-of-view. This novel approach delivers high-resolution PET images previously available only through organ-specific PET scanner while maintaining the imaging field-of-view of a clinical PET/CT scanner to see the entire body...
September 27, 2023: PET Clinics
https://read.qxmd.com/read/37775371/innovations-in-small-animal-pet-instrumentation
#27
REVIEW
Adrienne L Lehnert, Robert S Miyaoka
Biomedical research has long relied on small-animal studies to elucidate disease process and develop new medical treatments. The introduction of in vivo functional imaging technology, such as PET, has allowed investigators to peer inside their subjects and follow disease progression longitudinally as well as improve understanding of normal biological processes. Recent developments in CRISPR, immuno-PET, and high-resolution in vivo imaging have only increased the importance of small-animal, or preclinical, PET imaging...
September 27, 2023: PET Clinics
https://read.qxmd.com/read/37718218/whole-gamma-imaging-challenges-and-opportunities
#28
REVIEW
Taiga Yamaya, Hideaki Tashima, Sodai Takyu, Miwako Takahashi
Compton imaging has been recognized as a possible nuclear medicine imaging method following the establishment of SPECT and PET. Whole gamma imaging (WGI), a combination of PET and Compton imaging, could be the first practical method to bring out the potential of Compton imaging in nuclear medicine. With the use of such positron emitters as 89 Zr and 44 Sc, WGI may enable highly sensitive imaging of antibody drugs for early tumor detection and quantitative hypoxia imaging for effective tumor treatment...
September 15, 2023: PET Clinics
https://read.qxmd.com/read/37257985/current-status-of-fibroblast-activation-protein-imaging-in-gynecologic-malignancy-and-breast-cancer
#29
REVIEW
Katharina Dendl, Stefan A Koerber, Tadashi Watabe, Uwe Haberkorn, Frederik L Giesel
68Ga-FAPI-PET/computed tomography (CT) is a novel PET/CT radiotracer particularly developed for oncologic imaging. Gynecologic malignancies comprise a broad spectrum of entities and, along with breast cancer, constitute cancers occurring exclusively or primarily, respectively, in women. Thus, a tracer designed not only for one but multiple malignancies has theoretic attractions. Even in comparison with 18F-FDG, the current standard oncologic tracer of nuclear medicine, 68Ga-FAPI, has demonstrated advantages in several tumors...
July 2023: PET Clinics
https://read.qxmd.com/read/36997365/fibroblast-activation-protein-inhibitor-theranostics-preclinical-considerations
#30
REVIEW
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Tadashi Watabe
Fibroblast activation protein (FAP) was first reported in 1986. However, FAP is not expressed in normal fibroblasts, normal or malignant epithelial cells, or the stroma of benign epithelial tumors. FAP is a cell membrane-bound serine peptidase overexpressed on the surface of cancer-associated fibroblasts and, as such, is a novel target for molecular imaging of several tumors. FAP inhibitors (FAPI) are potential theranostic molecular probes for various cancers. A tumor model expressing FAP was used to verify or confirm the usefulness of FAPI experimentally...
July 2023: PET Clinics
https://read.qxmd.com/read/37369615/other-novel-pet-radiotracers-for-breast-cancer
#31
REVIEW
Sophia R O'Brien, Rebecca Ward, Grace G Wu, Sina Bagheri, Mahsa Kiani, Ashrit Challa, Gary A Ulaner, Austin R Pantel, Elizabeth S McDonald
Many novel PET radiotracers have demonstrated potential use in breast cancer. Although not currently approved for clinical use in the breast cancer population, these innovative imaging agents may one day play a role in the diagnosis, staging, management, and even treatment of breast cancer.
June 25, 2023: PET Clinics
https://read.qxmd.com/read/37369614/metabolic-positron-emission-tomography-in-breast-cancer
#32
REVIEW
Katherine Cecil, Laura Huppert, Rita Mukhtar, Elizabeth H Dibble, Sophia R O'Brien, Gary A Ulaner, Courtney Lawhn-Heath
Metabolic PET, most commonly 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT), has had a major impact on the imaging of breast cancer and can have important clinical applications in appropriate patients. While limited for screening, FDG PET/CT outperforms conventional imaging in locally advanced breast cancer. FDG PET/CT is more sensitive than conventional imaging in assessing treatment response, accurately predicting complete response or nonresponse in early-stage cases. It also aids in determining disease extent and treatment response in the metastatic setting...
June 25, 2023: PET Clinics
https://read.qxmd.com/read/37339919/human-epidermal-growth-factor-receptor-2-human-epidermal-growth-factor-receptor-3-pet-imaging-challenges-and-opportunities
#33
REVIEW
Maxwell Ducharme, Ameer Mansur, Luke Sligh, Gary A Ulaner, Suzanne E Lapi, Anna G Sorace
Human epidermal growth factor receptor 2 (HER2) and HER3 provide actionable targets for both therapy and imaging in breast cancer. Further, clinical trials have shown the prognostic impact of receptor status discordance in breast cancer. Intra- and intertumoral heterogeneity of both HER and hormone receptor expression contributes to inherent errors in tissue sampling, and single biopsies are incapable of identifying discordance in biomarker expression. Numerous PET radiopharmaceuticals have been developed to evaluate (or target for therapy) HER2 and HER3 expression...
June 18, 2023: PET Clinics
https://read.qxmd.com/read/37330407/breast-cancer-advances-in-molecular-imaging
#34
EDITORIAL
Gary A Ulaner, Amy M Fowler
No abstract text is available yet for this article.
June 15, 2023: PET Clinics
https://read.qxmd.com/read/37291018/evaluation-of-treatment-response-in-patients-with-breast-cancer
#35
REVIEW
Saima Muzahir, Gary A Ulaner, David M Schuster
Breast cancer (BC) remains one of the leading causes of death among women. The management and outcome in BC are strongly influenced by a multidisciplinary approach, which includes available treatment options and different imaging modalities for accurate response assessment. Among breast imaging modalities, MR imaging is the modality of choice in evaluating response to neoadjuvant therapy, whereas F-18 Fluorodeoxyglucose positron emission tomography, conventional computed tomography (CT), and bone scan play a vital role in assessing response to therapy in metastatic BC...
June 6, 2023: PET Clinics
https://read.qxmd.com/read/37270377/estrogen-receptor-targeted-and-progesterone-receptor-targeted-pet-for-patients-with-breast-cancer
#36
REVIEW
Gary A Ulaner, Amy M Fowler, Amy S Clark, Hannah Linden
Estrogen receptor (ER)-targeted imaging with 16α-18 F-fluoro-17β-fluoroestradiol (18 F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of 18 F-FES PET for patients with ER-positive breast cancer...
June 1, 2023: PET Clinics
https://read.qxmd.com/read/37268506/breast-cancer-systemic-staging-comparison-of-computed-tomography-bone-scan-and-18f-fluorodeoxyglucose-pet-computed-tomography
#37
REVIEW
David Groheux
After an overview of the principles of bone scintigraphy, contrast-enhanced computed tomography (CE-CT) and 18F-fluorodeoxyglucose (FDG)-PET/CT, the advantages and limits of these modalities in the staging of breast cancer are discussed in this paper. CT and PET/CT are not optimal for delineating primary tumor volume, and PET is less efficient than the sentinel node biopsy to depict small axillary lymph node metastases. In large breast cancer tumor, FDG PET/CT is useful to show extra-axillary lymph nodes. FDG PET/CT is superior to bone scan and CE-CT in detecting distant metastases, and it results in a change of treatment plan in nearly 15% of patients...
May 31, 2023: PET Clinics
https://read.qxmd.com/read/37268505/molecular-classification-of-breast-cancer
#38
REVIEW
Madhuchhanda Roy, Amy M Fowler, Gary A Ulaner, Aparna Mahajan
Breast carcinomas classified based on traditional morphologic assessment provide useful prognostic information. Although morphology is still the gold standard of classification, recent advances in molecular technologies have enabled the classification of these tumors into four distinct subtypes based on its intrinsic molecular profile that provide both predictive and prognostic information. This article describes the association between the different molecular subtypes with the histologic subtypes of breast cancer and illustrates how these subtypes may affect the appearance of tumors on imaging studies...
May 31, 2023: PET Clinics
https://read.qxmd.com/read/37258343/molecular-breast-imaging-and-positron-emission-mammography
#39
REVIEW
Miral M Patel, Beatriz Elena Adrada, Amy M Fowler, Gaiane M Rauch
There is growing interest in application of functional imaging modalities for adjunct breast imaging due to their unique ability to evaluate molecular/pathophysiologic changes, not visible by standard anatomic breast imaging. This has led to increased use of nuclear medicine dedicated breast-specific single photon and coincidence imaging systems for multiple indications, such as supplemental screening, staging of newly diagnosed breast cancer, evaluation of response to neoadjuvant treatment, diagnosis of local disease recurrence in the breast, and problem solving...
May 29, 2023: PET Clinics
https://read.qxmd.com/read/37121834/fibroblast-activation-protein-as-a-diagnostic-and-therapeutic-target-where-do-we-go-from-here
#40
EDITORIAL
Rodney J Hicks, Frederik Giesel, Ken Herrmann
No abstract text is available yet for this article.
April 28, 2023: PET Clinics
journal
journal
41201
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.